Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

October 12, 2017: By Jon Swedien

NicoxNicox and pSivida have agreed to potentially combine Nicox’s nitric oxide (NO)-donating compounds with pSivida’s bioerodible sustained-release drug delivery system to develop an IOP-lowering treatment for glaucoma and ocular hypertension, the companies announced Oct. 10.

Nicox and pSivida will collaborate on the selection of NO-donating product candidates from Nicox’s research portfolio to combine with pSivida’s technology. pSivida will be responsible for initial development activities and receive undisclosed payments from Nicox, the companies said.

pSividaThe firms may elect to conduct more detailed nonclinical studies to generate preclinical data and evaluate additional compounds. Nicox would make additional payments for any incremental development activities for each product candidate selected by Nicox to advance, the companies said.

New intellectual property from the collaboration will be jointly owned, the companies said. Nicox and pSivida will negotiate a separate license agreement for any product candidate they plan to commercialize under the collaboration, they said.

Expected payments from Nicox associated with this agreement are not considered material to Nicox’s financial statements at this time, the company said.

Nicox is an international ophthalmic company based in Paris. pSivida, headquartered in Watertown, Massachusetts, is focused on sustained-release drug products for treating eye diseases.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Optical Coherence Tomography Report: A Global Market Analysis for 2017 to 2023